Drug intelligence / Profile preview

LQ087

Development stage
Preclinical
Lead developer
Novamab Biopharmaceuticals
Modality
Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration
Oral
01

Overview

LQ087 is a preclinical-stage bispecific VHH nanobody developed by Novamab for the treatment of inflammatory bowel disease (IBD) and psoriasis. It is uniquely designed for oral administration, aiming to provide localized therapeutic action within the gastrointestinal tract while improving patient compliance compared to injectable biologics. The molecule simultaneously targets and inhibits two key pro-inflammatory cytokines: tumor necrosis factor-like ligand 1A (TL1A) and the p19 subunit of interleukin-23 (IL-23p19). By blocking these synergistic pathways, LQ087 is intended to offer enhanced anti-inflammatory efficacy for chronic autoimmune conditions.

02

Targets

IL23A (Interleukin-23 p19 Subunit)TL1A (TNF-like cytokine 1A)

Beyond the preview

Go deeper on LQ087.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on LQ087.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call